Cardiologist

Board certification
Cardiovascular disease and internal medicine

Education
Cardiologist James Erdahl, MD, earned his medical degree from Hahnemann Medical College, Philadelphia, Penn. He completed his internal medicine residency at Abington Memorial Hospital, Abington, Penn. He completed his fellowship in cardiology at the University of Minnesota, Minneapolis, Minn.

Special medical interests
Coronary artery disease, acute myocardial infarction, stress echocardiography and preventive cardiology.

Awards and honors
Named Top Doc in cardiology by Mpls/St Paul magazine, 2006.

For appointments
952-924-9005

Clinic location
Minnesota Heart Clinic
305 East Nicollet Blvd.
Ridgeview Office Bldg.
Suite 372
Burnsville, MN 55337


Research experience
Sub-investigator in the following clinical trials:

TIMI II - Thrombolysis in Acute Myocardial Infarction. (1987-1998)

CAST and CAST II - Cardia Arrhythmias Suppression Trial. (1987-1991)

SOLVD - Studies on Left Ventricular Dysfunction.  (1989-1991)

TTOPP - Thrombolytic Therapy in an Older Population.  (1989-1990)

USNA, t-PA in Unstable Angina (1988-1989)

Digitalis Investigation Group.

PROMISE - Prospective Randomization Milrinone Survival Evaluation Trial.  (1989-1991)

GUSTO I - Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.  (1990-1993)

GUSTO IIb and GUSTO IIb Angiographic Substudy - Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. (1994-1995)

CARS - Coumadin Aspirin Reinfarction Study. (1993-1996)                                

GUSTO III - Global Use of Strategies to Open Occluded Coronary Arteries Project:  A Randomized Trial of Reteplase (r-PA) versus Accelerated Alteplase (t-PA) for the Treatment of Acute Myocardial Infarction.  (1995-1997)

A Coronary Stent Pilot Study.  (1995-1996)                                            

InTime II - Double-blind, Randomized, Multicenter Trial of Single Bolus Lanoteplase Versus Accelerated Alteplase for the Treatment of Subjects with Acute Myocardial Infarction.  (1997 -2000)

SYMPHONY - A Phase III, Multicenter, International, Randomized, Double-blind, Aspirin-controlled Trial to Evaluate the Efficacy and Safety of Sibrafiban (R048-3657), an Oral Platelet Glycoprotein IIb/IIIa Antagonist, a Therapy for the Prevention of Secondary Vascular Events in Patients after and Acute Coronary Syndrome. (1997 Ongoing)

2nd SYMPHONY Trial: A phase III, Multicenter, International, Randomized, Double-blind, Aspirin-Controlled Trial to Evaluate the Efficacy and Safety of Two Regimens with Xubix? (Sibrafiban: Ro 48-3657), an Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonist, as Therapy for the Long Term Prevention of Secondary Vascular Events in Patients After an Acute Coronary Syndrome, 1998 - present

ALIVE Study: A Double-blind, Placebo-Controlled, Parallel Design Study to Determine the Effect of 75mg or 100mg of Orally Administered Azimilide Dihydrochloride versus Placebo on Survival in Recent Post-Myocardial Infarction Patients at Risk of Sudden Death, 1998 - present

 AMISTAD II Trial: “A Randomized, Double-blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Adenosine (Pallacor?, Adenosine Injection) as an Adjunct to Reperfusion Therapy (Thrombolysis or Mechanical Reperfusion) in the Treatment of Acute Anterolateral Myocardial Infarction”, 8/99 – ongoing

back